What We’re Doing

We have developed a broad-based gene editing platform that utilizes a unique CRISPR/Cas biomolecular tool to disable genes in tumor cells responsible for drug resistance.  We are focused on our initial target of treatment for squamous cell carcinoma of the head & neck. Our platform technology is also being tested in squamous cell carcinomas of the lung, esophagus, and pancreas, as well as melanoma, and glioblastoma. The CorriXR delivery system is a proven lipid nanoparticle approach that when combined with direct intratumoral injection minimizes off-target effects.